United Therapeutics Corporation $UTHR Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 82.7% in the fourth quarter, Holdings Channel reports. The firm owned 7,021 shares of the biotechnology company’s stock after purchasing an additional 3,179 shares during the quarter. Daiwa Securities Group Inc.’s holdings in United Therapeutics were worth $3,421,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Torren Management LLC acquired a new position in United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC grew its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the fourth quarter worth about $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.9%

Shares of NASDAQ UTHR opened at $544.69 on Tuesday. The firm’s 50-day moving average price is $568.47 and its two-hundred day moving average price is $519.64. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market capitalization of $23.12 billion, a P/E ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the business earned $6.63 EPS. The business’s revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 624,043 shares of company stock valued at $351,930,785 over the last quarter. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.